Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Dec 21;32(12):711–717. doi: 10.1002/clc.20617

Plasma N‐Terminal Protype‐B Natriuretic Peptide and Restrictive Mitral Flow to Risk‐stratify Patients with Stage B Heart Failure

Frank L Dini 1,2,✉, Gillian Whalley 3, Katrina Poppe 3, Paolo Fontanive 1, Gian Marco Rosa 2, Robert N Doughty 3, Vitantonio Di Bello 4
PMCID: PMC6653230  PMID: 20027664

Abstract

Background

The prognostic role of echocardiography is well established in patients with previous or current symptoms of heart failure (HF). Less is understood about patients with stage B HF, who have structural heart disease but no symptoms at any stage. This study investigated the role of plasma N‐terminal protype‐B natriuretic peptide (NT‐proBNP) and Doppler‐echo parameters of diastolic and systolic function for risk stratification in stage B HF patients.

Hypothesis

We investigated whether plasma NT‐proBNP and Doppler‐echo parameters of diastolic and systolic function have a role in risk stratification of stage B HF patients.

Methods

Doppler echocardiography was performed in 155 outpatients with asymptomatic left ventricular (LV) dysfunction (ejection fraction [EF] < 50%) and comprised conventional diastolic variables, including pulsed‐Doppler mitral E‐wave deceleration time (EDT). Plasma NT‐proBNP was assessed at the time of the echocardiogram. The prespecified end point was cardiac death or HF hospitalization or any new HF episode requiring a change in medication.

Results

Mean EF was 35% ± 7%. Median NT‐proBNP was 745 pg/mL (interquartile range [IQR], 442–1672). Patients with events at follow‐up (n = 46) had higher prevalence of risk factors for developing HF. Plasma NT‐proBNP, EDT, and EF were independently associated with cardiac events at multivariable analysis and receiver operating characteristic curves were used to determine the optimal prognostic cut points for each: NT‐proBNP ≥ 831 pg/mL, EDT < 145 msec, and EF < 37%. When used in combination, event‐free survival was incrementally worse with each additional abnormality.

Conclusion

Plasma NT‐proBNP, EDT, and EF are independently useful for prognostic stratification of stage B HF patients and suggest an incremental prognostic deficit is associated with the combination of each. This study supports the complementary role of comprehensive echocardiography and natriuretic peptide assay in asymptomatic LV dysfunction. Copyright © 2009 Wiley Periodicals, Inc.

Full Text

The Full Text of this article is available as a PDF (2.4 MB).

References

  • 1. Hunt SA; American College of Cardiology; American Heart Association Task Force on Practice Guidelines. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005; 46: 1–82. [DOI] [PubMed] [Google Scholar]
  • 2.Meta‐analysis Research Group in Echocardiography (MeRGE) Heart Failure Collaborators. Independence of restrictive filling pattern and LV ejection fraction with mortality in heart failure: an individual patient meta‐analysis. Eur J Heart Fail 2008; 10: 786–792. [DOI] [PubMed] [Google Scholar]
  • 3. Nagueh S, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009; 22: 107–133. [DOI] [PubMed] [Google Scholar]
  • 4. Logeart D, Thabut G, Jourdain P, et al. Predischarge B‐type natriuretic peptide assay for identifying patients at high risk of re‐admission after decompensated heart failure. J Am Coll Cardiol 2004; 43: 635–641. [DOI] [PubMed] [Google Scholar]
  • 5. Bettencourt P, Azevedo A, Pimenta J, et al. N‐terminal‐pro‐brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004; 110: 2168–2174. [DOI] [PubMed] [Google Scholar]
  • 6. Gardner RS, Ozalp E, Murday AJ, Robb SD, McDonagh TA. N‐terminal pro‐brain natriuretic peptide. A gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 2003; 24: 1735–1743. [DOI] [PubMed] [Google Scholar]
  • 7. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993; 88: 107–155. [DOI] [PubMed] [Google Scholar]
  • 8. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18: 1440–1463. [DOI] [PubMed] [Google Scholar]
  • 9. Dini FL, Fontanive P, Buralli S, et al. N‐terminal protype‐B natriuretic peptide and Doppler diastolic variables are incremental for risk stratification of patients with NYHA class I‐II systolic heart failure. Int J Cardiol Epub ahead of print 2008. [DOI] [PubMed] [Google Scholar]
  • 10. Quinones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA: Recommendations for quantification of Doppler echocardiography: A report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr 2002; 15: 167–184. [DOI] [PubMed] [Google Scholar]
  • 11. Yamada H, Goh P‐P, Sun JP, et al. Prevalence of left ventricular diastolic dysfunction by Doppler echocardiography: Clinical application of the Canadian Consensus Guidelines. J Am Soc Echocardiogr 2002; 15: 1238–1244. [DOI] [PubMed] [Google Scholar]
  • 12. Youden W. Index for rating diagnostic tests. Cancer 1950; 3: 32–35. [DOI] [PubMed] [Google Scholar]
  • 13. Wang TJ, Evans JC, Benjamin EJ, et al. Natural history of asymptomatic left ventricular dysfunction in the community. Circulation 2003; 108: 977–982. [DOI] [PubMed] [Google Scholar]
  • 14. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with or without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82: 1724–1729. [DOI] [PubMed] [Google Scholar]
  • 15. Frigerio M, Oliva F, Turrazza FM, Bonow RO. Prevention and management of chronic heart failure in management of asymptomatic patients. Am J Cardiol 2003; 91: 4–9. [DOI] [PubMed] [Google Scholar]
  • 16. Goldberg LR, Jessup MR. Stage B heart failure: management of asymptomatic left ventricular systolic dysfunction. Circulation 2006; 113: 2851–2860. [DOI] [PubMed] [Google Scholar]
  • 17. Galasko GI, Barnes SC, Collinson P, Lahiri A, Senior R. What is the most cost‐effective strategy to screen for left ventricular systolic dysfunction: natriuretic peptides, the electrocardiogram, hand‐held echocardiography, traditional echocardiography, or their combination? Eur Heart J 2006; 27: 193–200. [DOI] [PubMed] [Google Scholar]
  • 18. Goode KM, Clark Al, Bristow JA, Sykes KB, Cleland JG. Screening for left ventricular systolic dysfunction in high‐risk patients in primary‐care: a cost‐benefit analysis. Eur J Heart Fail 2007; 9: 1186–1195. [DOI] [PubMed] [Google Scholar]
  • 19. Baker DW, Bahler RC, Finkelhor RS, Lauer MS. Screening for left ventricular systolic dysfunction among patients with risk factors for heart failure. Am Heart J 2003; 146: 736–740. [DOI] [PubMed] [Google Scholar]
  • 20. Baggish Al, van Kimmenade RR, Januzzi JL Jr. The differential diagnosis of an elevated amino‐terminal pro‐B‐type natriuretic peptide level. Am J Cardiol 2008; 101(3A): 43–48. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES